board header new
mobile header 3

The Immulytic Platform

We believe that our ‘Immulytic’ oncolytic immunotherapy platform will become a second cornerstone of immuno-oncology, in addition to anti-PD1/L1. The Immulytic platform has been developed to provide both maximum local tumor destruction & antigen release, and maximum systemic anti-tumor immune stimulation.

The Immulytic platform also bundles multiple products into one. It produces a universal neo-antigen vaccine, directly in situ in the patient, generates an inflamed tumor, and triggers innate immunity. It additionally expresses powerful immune stimulatory proteins providing optimal T cell activation. Direct delivery to the tumor & draining lymph nodes is intended to overcome systemic toxicity & low potency of other approaches due to off target effects.